Literature DB >> 6767449

Prophylaxis of venous thromboembolism: analysis of cost effectiveness.

E W Salzman, G C Davies.   

Abstract

The rapidly expanding literature regarding prevention of venous thromboembolism is confusing and contradictory, but, when analysed in the aggregate, the collective experience permits a judgment about the relative efficacy of different prophylactic regimens in specific patient populations, who vary in the risk factors predisposing them to thromboembolism. The dollar cost of the several approaches to prevention and their consequences should also be a matter of concern. Efficacy and dollar cost together determine cost effectiveness, which provides a practical guide to selection of the prophylactic approach appropriate to an individual patient.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767449      PMCID: PMC1345610          DOI: 10.1097/00000658-198002000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  111 in total

1.  Postoperative deep-vein thrombosis. Effect of intensive prophylaxis.

Authors:  C Flanc; V V Kakkar; M B Clarke
Journal:  Lancet       Date:  1969-03-08       Impact factor: 79.321

2.  The effect of Dextran '70'* on post-operative deep venous thrombosis.

Authors:  D London; M L Crosfill
Journal:  Br J Clin Pract       Date:  1969-04

3.  Heparin in the treatment of venous thrombo-embolic disease: administration, control and results.

Authors:  E F O'Sullivan; J Hirsh; R A McCarthy; G C de Gruchy
Journal:  Med J Aust       Date:  1968-07-27       Impact factor: 7.738

4.  125-I-labelled fibrinogen in the diagnosis of deep-vein thrombosis and its correlation with phlebography.

Authors:  D Negus; D J Pinto; L P Le Quesne; N Brown; M Chapman
Journal:  Br J Surg       Date:  1968-11       Impact factor: 6.939

5.  The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen.

Authors:  C Flanc; V V Kakkar; M B Clarke
Journal:  Br J Surg       Date:  1968-10       Impact factor: 6.939

6.  Ligation of inferior vena cava for thromboembolism. Clinical and autopsy correlations in 119 cases.

Authors:  E Amador; T K Li; C Crane
Journal:  JAMA       Date:  1968-11-18       Impact factor: 56.272

7.  Heparin therapy in thromboembolic disease.

Authors:  R J Kernohan; C Todd
Journal:  Lancet       Date:  1966-03-19       Impact factor: 79.321

8.  Arthroplasty of the hip for idiopathic degenerative joint disease.

Authors:  J C Ivins; W F Benson; W H Bickel; J W Nelson
Journal:  Surg Gynecol Obstet       Date:  1967-12

9.  The prevention of thromboembolic disease by prophylactic anticoagulation. A controlled study in elective hip surgery.

Authors:  W H Harris; E W Salzman; R W Desanctis
Journal:  J Bone Joint Surg Am       Date:  1967-01       Impact factor: 5.284

10.  Hemorrhage during long-term anticoagulant drug therapy. 1. Intracranial hemmorrhage.

Authors:  J M Askey
Journal:  Calif Med       Date:  1966-01
View more
  24 in total

Review 1.  [An update on thrombosis prophylaxis in orthopaedic and accident surgery].

Authors:  J Grifka; S Haas; L Hovy; W Knopp; H L Refior; M Schürmann; T Wirth
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 3.  Venous thromboembolism: epidemiology, diagnosis, prevention.

Authors:  D M Becker
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

4.  Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost effectiveness in The Netherlands.

Authors:  W E Mol; T C Egberts
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 5.  Economics of thromboprophylaxis in total hip replacement surgery.

Authors:  J Harrison; D J Warwick; J Coast
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 6.  Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Authors:  D R Anderson; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 7.  Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.

Authors:  M T Nurmohamed; H R Büller; J W ten Cate
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

8.  Dextran prophylaxis of fatal pulmonary embolism.

Authors:  K G Ljungström
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

9.  Multicentre hospital drug utilization study on the prophylaxis of venous thromboembolism. The Venous Thromboembolism Study Group of the Spanish Society of Clinical Pharmacology.

Authors:  J A Vallès; A Vallano; F Torres; J M Arnau; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 10.  Venous thromboembolism in Pakistan: a neglected research agenda.

Authors:  Abdul Ahad Khan; Syed Nabeel Zafar
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.